Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Amyloidosis × belantamab mafodotin × Clear all

Phase

Status

Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 12 Recurrence 3 Neoplasms, Plasma Cell 2 Immunoglobulin Light-chain Amyloidosis 1 Amyloidosis 1

Interventions

pomalidomide 1 daratumumab 1 belantamab mafodotin 1 Lenalidomide 1 Hyaluronoglucosaminidase 1 Dexamethasone 1 Cyclophosphamide 1 Bortezomib 1 Antineoplastic Protocols 1 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05145816 2026-02-17

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

University of Texas Southwestern Medical Center

Phase 1/2 Recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡